The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes
Authors:
- Hajime MaedaHMHajime Maeda
- Akira KubotaAKAkira Kubota
- Yasushi TanakaYTYasushi Tanaka
- Yasuo TerauchiYTYasuo Terauchi
- Ikuro MatsubaIMIkuro Matsuba
- 1 January 2012
- journal article
- research article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 95 (1) , e20-e22
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- The effect of initial therapy with the fixed‐dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2011
- Dipeptidyl peptidase‐4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta‐analysis of randomized controlled trialsDiabetes, Obesity and Metabolism, 2011
- Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetesInternational Journal Of Clinical Practice, 2011
- Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?Diabetologia, 2010
- Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year studyInternational Journal Of Clinical Practice, 2010
- Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic menEndocrine Journal, 2010
- Effect of Sitagliptin, a Dipeptidyl Peptidase‐4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate HypertensionThe Journal of Clinical Pharmacology, 2008
- Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetesCurrent Medical Research and Opinion, 2008
- Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 DiabetesDiabetes Care, 2007
- Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metforminDiabetes, Obesity and Metabolism, 2007